ISTH Congress Abstracts

Official abstracts site for the ISTH Congress

MENU 
  • Home
  • Congress Archive
    • ISTH 2021 Congress
    • ISTH 2020 Congress
  • Resources
  • Search

ISTH 2021 Congress

July 17-21, 2021. Philadelphia, PA.

View by Title View by Number View Themes
Jump to:  [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z
  • Abstract Number: PO188

    “Heparin Failure” in Seminoma-related Dramatic Hypercoagulable Melieu and Extended Vein Thrombosis: Is it BEP Protocol Ongoing Responsible?

    A.M. Fioretti1, T. Leopizzi1, L. Palermo2, V. Lorusso2, S. Oliva1

  • Abstract Number: PB0016

    “Red Cardiac versus White Atherosclerotic Thromboemboli in Acute Ischemic Stroke”: Challenging the Concept via a Large-scale, Detailed Multi-parametric Histological Analysis

    S. Staessens1, O. François2, E. Boulleaux3, D. Corseaux3, L. Desender1, A. Vandenbulcke1, J. de Boer4, C. Vens4, A.-S. De Sloovere2, T. Dewaele2, P. Vanacker5,6,7, S. Susen3,8, K. Vanhoorelbeke1, C. Cordonnier9, T. Andersson2,10, S.F. De Meyer1

  • Abstract Number: OC 28.4

    Candida albicans Expresses an Integrin-like Protein that Promotes Endothelial Attachment and Vascular Leakage during Fungal Sepsis

    D. Nader1, G. Curley1, S. Kerrigan1

  • Abstract Number: OC 30.3

    CDKN2A Mutational Status is Associated with Venous Thromboembolism in Patients with Glioblastoma

    M.Y. Kapteijn1, F.H. Kaptein1, M.A. Stals1, E.E. Klaase1, R. van Eijk1, S.C. Cannegieter1, S.G. van Duinen1, M.J. Taphoorn1, L. Dirven1, J.A. Koekkoek1, F.A. Klok1, H.H. Versteeg1, J.T. Buijs1

  • Abstract Number: OC 32.1

    Ex vivo Assessment of the Importance of Activated Factor IX (FIXa) Levels in the Procoagulant Effect of Recombinant FIX Concentrates in Emicizumab-treated Patients

    E.G Arias-Salgado1, E. Monzón Manzano1, P. Acuña1, I. Fernández-Bello1, S. García Barcenilla1, M.T. Álvarez Román1, M. Martín1, M.I. Rivas Pollmar1, T. Cebanu1, E. González Zorrilla1, N. Butta1, V. Jiménez-Yuste1,2

  • Abstract Number: PB0057

    Ex vivo Evaluation of the Effect of Plasma-derived Factor VIII/von Willebrand Factor in Patients with Severe Hemophilia A on Prophylaxis with Emicizumab by ROTEM

    E. Monzón Manzano1, E. Arias-Salgado1, P. Acuña1, M.-I. Bravo2, A. Raventos2, A. Perez2, M.T. Álvarez Román1, N. Butta1, M. Costa2, T. Willis3, V. Jimenez-Yuste1,4

  • Abstract Number: PB0326

    In silico Methods of Structural Biology for Studying (Not Only) Coagulation Proteins

    Z. Sovova1, J. Suttnar1, J.E. Dyr1

  • Abstract Number: OC 75.3

    In vitro and In vivo Models to Understand One-stage and Chromogenic Factor VIII Activity Assay Discrepancy of Hepatocyte-derived Factor VIII

    A.R. Sternberg1,2, R.J Davidson1,2, B.J Samelson-Jones1,2,3, L.A George1,2,3

  • Abstract Number: PB0375

    In vitro Neutralization of Low Molecular Weight Heparins for the Measurement of Fibrin Polymerization Profile and Coagulation-fibrinolysis Balance

    M.-A. Bildan1, M. Lambert1, S. Fontaine1, O. Mathieu1, G. Contant1

  • Abstract Number: OC 04.4

    13C Metabolic Flux Analysis in Resting and Thrombin Activated Platelets

    C. Sake1, K. Neeves2, N. Boyle1

  • Abstract Number: PB0608

    MOdern Treatment of Inhibitor-PositiVe PATiEnts with Haemophilia A – MOTIVATE (www.motivate-study.com)

    C. Escuriola Ettingshausen1, R.F. Sidonio, Jr.2

  • Abstract Number: PB0627

    PRactical Utilisation of Octapharma FVIII Concentrates in Previously Untreated and Minimally Treated Haemophilia A Patients Entering Routine Clinical Treatment with Nuwiq®, octanate® or wilate® – The Protect-NOW Study

    J. Oldenburg1, P.M. Vera2, S. Halimeh3, R. Klamroth4, S. Lowndes5, M. Jansen6

  • Abstract Number: PB0594

    2 Years ofPprophylaxis with rFVIII-Fc in Haemophilia in a Portuguese Haemophilia Center: Did Doctors and Patients See a Change?

    S. Campaniço1, F. Rodrigues1, A. Pereira1, J. Amorim1, C. Correia1, L. Parusnikova1, C. Catarino1

  • Abstract Number: OC 64.2

    25mmHg vs. 35mmHg Elastic Compression Stockings to Prevent Post Thrombotic Syndrome after Deep Vein Thrombosis: The CELEST Double-blind Trial

    J.P. Galanaud1, C. Genty-Vermorel2, M.T. Barrellier3, F. Becker4, I. Bertaina5, S. Blaise6, A. Bura Riviere7, A. Comte6, C. Grange8, H. Guenneguez9, M. Maufus10, P. Ouvry9, C. Richaud6, C. Rolland6, J. Schmidt11, M.A. Sevestre12, F. Verrière5, J.-L. Bosson6, CELEST Trial Investigators

  • Abstract Number: OC 25.3

    36-month Clinical Outcomes of Patients with Venous Thromboembolism: GARFIELD-VTE

    A.G.G. Turpie1, A.E. Farjat2, S. Haas3, W. Ageno4, J.I. Weitz5, S.Z. Goldhaber6, S. Goto7, P. Angchaisuksiri8, G. Kayani2, R.D. Lopes9, C.E. Chiang10,11, H. Gibbs12, E. Tse13, P. Verhamme14, H. Ten Cate15, J. Muntaner16, S. Schellong17, H. Bounameaux18, P. Prandoni19, A.K. Kakkar2,20

  • Abstract Number: PB0653

    52 Week Efficacy and Safety of Etranacogene Dezaparvovec in Adults with Severe or Moderate-severe Hemophilia B: Data from the Phase 3 HOPE-B Gene Therapy Trial

    S.W Pipe1, F.W. Leebeek2, M. Recht3, N.S Key4, S. Lattimore3, G. Castaman5, E.K Sawyer6,7, S. Verweij6,7, V. Colletta6,7, D. Cooper6,7, R. Dolmetsch6,7, W. Miesbach8, HOPE-B Investigators

  • Abstract Number: PB1040

    A 3D in vitro Model of Inflammation-associated Bleeding

    R. Riddle1, K. Hansson2, K. Jennbacken2, M. Harper1

  • Abstract Number: PB0784

    A 5-Year Study of Arterial and Venous Thromboses in Greek Infants, Children and Adolescents. Comparison of Data Before and during the Pandemic Period

    L. Ioannidou1, A. Dettoraki1, A. Michalopoulou1, Z. Kapsimali1, S. Saslis1, M. Mazarakis1, H. Pergantou1

  • Abstract Number: PB0624

    A Bleed Suppression Efficacy of Emicizumab in Patients with Hemophilia A whose Therapies Switched from Conventional Prophylaxis

    T. Fujii1, N. Yamasaki1, T. Inoue1, T. Fujii1

  • Abstract Number: OC 48.1

    A Blood Coagulation Factor IX Variant that Functions Independently of Factor VIII Mitigates the Hemophilia A Phenotype in Patient Plasma

    V.J. Strijbis1, L.G. Romano2, K.L. Cheung1, Y.P. Liu3, A.C. McCreary3, F.W. Leebeek2, M.H. Bos1

  • 1
  • 2
  • 3
  • …
  • 91
  • Next Page »
Jump to:  [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2022 John Wiley & Sons, Inc. All Rights Reserved.
Wiley